Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature
Open Access
- 16 July 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 27 (4), 441-449
- https://doi.org/10.1038/sj.onc.1210661
Abstract
Human neuroblastoma remains enigmatic because it often shows spontaneous regression and aggressive growth. The prognosis of advanced stage of sporadic neuroblastomas is still poor. Here, we investigated whether genomic and molecular signatures could categorize new therapeutic risk groups in primary neuroblastomas. We conducted microarray-based comparative genomic hybridization (array-CGH) with a DNA chip carrying 2464 BAC clones to examine genomic aberrations of 236 neuroblastomas and used in-house cDNA microarrays for gene-expression profiling. Array-CGH demonstrated three major genomic groups of chromosomal aberrations: silent (GGS), partial gains and/or losses (GGP) and whole gains and/or losses (GGW), which well corresponded with the patterns of chromosome 17 abnormalities. They were further classified into subgroups with different outcomes. In 112 sporadic neuroblastomas, MYCN amplification was frequent in GGS (22%) and GGP (53%) and caused serious outcomes in patients. Sporadic tumors with a single copy of MYCN showed the 5-year cumulative survival rates of 89% in GGS, 53% in GGP and 85% in GGW. Molecular signatures also segregated patients into the favorable and unfavorable prognosis groups (P=0.001). Both univariate and multivariate analyses revealed that genomic and molecular signatures were mutually independent, powerful prognostic indicators. Thus, combined genomic and molecular signatures may categorize novel risk groups and confer new clues for allowing tailored or even individualized medicine to patients with neuroblastoma.Keywords
This publication has 29 references indexed in Scilit:
- MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screeningBritish Journal of Cancer, 2006
- Neuroblastoma, Well-Designed Evaluations, and the Optimality of Research Funding: Ask Not What Your Country Can Do for You …JNCI Journal of the National Cancer Institute, 2005
- Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsetsOncogene, 2003
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences of the United States of America, 2003
- Chromosomes that show partial loss or gain in near‐diploid tumors coincide with chromosomes that show whole loss or gain in near‐triploid tumors: Evidence suggesting the involvement of the same genes in the tumorigenesis of high‐ and low‐risk neuroblastomasGenes, Chromosomes and Cancer, 2002
- High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastomaOncogene, 2000
- Deletion of chromosome 11 and of 14q sequences in neuroblastomaGenes, Chromosomes and Cancer, 1993
- Association between High Levels of Expression of the TRK Gene and Favorable Outcome in Human NeuroblastomaNew England Journal of Medicine, 1993
- Neuroblastoma: The result of multistep transformation?The International Journal of Cell Cloning, 1993
- Cellular DNA Content as a Predictor of Response to Chemotherapy in Infants with Unresectable NeuroblastomaNew England Journal of Medicine, 1984